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Abstract: 
 
Herein we report the label-free detection of a cancer biomarker using newly developed arrayed 
nanostructured Fabry–Perot interferometer (FPI) microchips. Specifically, the prostate cancer 
biomarker free prostate-specific antigen (f-PSA) has been detected with a mouse anti-human 
PSA monoclonal antibody (mAb) as the receptor. Experiments found that the limit-of-detection 
of current nanostructured FPI microchip for f-PSA is about 10 pg/mL and the upper detection 
range for f-PSA can be dynamically changed by varying the amount of the PSA mAb 
immobilized on the sensing surface. The control experiments have also demonstrated that the 
immunoassay protocol used in the experiments shows excellent specificity and selectivity, 
suggesting the great potential to detect the cancer biomarkers at trace levels in complex 
biofluids. In addition, given its nature of low cost, simple-to-operation and batch fabrication 
capability, the arrayed nanostructured FPI microchip-based platform could provide an ideal 
technical tool for point-of-care diagnostics application and anticancer drug screen and discovery. 
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Article: 
 
1. Background 
 
The detection of cancers at their early stage is critical for the survival of the patients (Choi et al., 
2010; Ferrari, 2005). In the field of genomics and proteomics, a variety of technologies have 
been developed for biomarker discovery and early detection, such as various DNA microarrays 
(Food et al., 1991), DNA sequence methods (Farwell and Joshi (2009)), enzyme-linked 
immunosorbent assay (ELISA) (Zangar et al., 2006), two-dimensional polyarylamide gel 
electrophoresis (2D-PAGE) (Choe et al., 2006), mass spectrometry (Ackermann et al., 2006), 
proteomic pattern diagnostics (Petricoin et al., 2004), and protein/antibody microarrays 
(Stoevesandt et al., 2009). However, most of them suffer from a complicated fluorescent dye 
labeling process, bulk instrumentation and low sensitivity, and are not applicable for trace 
detection of biomarkers at the early stage of tumor diseases. For instance, sandwich ELISA is the 
gold standard in the detection and quantification of protein/cancer biomarkers (Imafuku et al., 
2004). But sandwich assays are not convenient for achieving large scale multiplexed 
measurements (Lee et al., 2008). On the other hand, most fluorescence imaging based techniques 
are incapable of providing sufficient sensitivity to monitor biomarker affinity at concentrations 
of around 10 pM or lower without some forms of signal amplification (Healy et al., 2007). The 
concentration of many clinically relevant biomarkers residing in biofluids (i.e., blood) is usually 
at picomolar concentrations or lower (Lee et al., 2008), about five to seven orders of magnitude 
lower than the most abundant plasma protein. Since there is no universal ultrasensitive enzymatic 
amplification method for proteins like polymerase chain reaction (PCR) for the detection of 
nucleic acid, thus a diagnostic tool with ultrasensitivity (picomolar, femtomolar concentration or 
lower) and high specificity is required. 
 
To this end, micro- and nano-technologies started to play a very important role in the 
enhancement of the sensitivity and detection limit of the biosensing technologies. A variety of 
different detection technologies based on micro- and nano-technologies have been developed in 
the past decades for the measurement of the tumor markers at a low concentration level, showing 
great promise for potential applications in point-of-care diagnostics and clinic settings. 
Representative technologies include fluorescence (Mukundan et al., 2009), light scattering (Liu 
et al., 2008), surface enhanced Raman spectroscopy (SERS) (Haynes et al., 2005), surface 
Plasmon resonance (SPR) (Smith and Corn, 2003), photonic crystals (Chan et al., 2008), 
electrochemical immunosensing electrodes (Wilson and Nie (2006)), quartz crystal microbalance 
(Henne et al., 2006), micro- or nano-cantilevers (Wu et al., 2000), nanowires (Zheng et al., 2005; 
Tian et al., 2011), carbon nanotubes (Star et al., 2006), nanoparticles based localized SPR (Nie 
and Emory (1997)), nanoholes and array (Yanik et al., 2005), quantum dots (Gao et al., 2004), 
magnetonanosensor (Gaster et al., 2009), nanopore thin film (Lin et al., 1997) technologies. 
Furthermore, recent technical advancement in nanofabrication, nanomaterial synthesis, 
micro/nanofluidics and bioassay has also enhanced the sensitivity or chip adaptability for the 
detection and quantification of protein biomarkers in biological samples via the binding to 
antibodies or aptamers (Zhou et al., 2007). 
 
Among these technologies, particularly related to this article is the label-free optical detection 
technique. Label-free technique is attractive for biosensing since no fluorescent dyes are needed 
to be attached to the biomolecules. As a result, the experimental cost can be reduced 
dramatically, and the possible perturbation of the properties of the biomolecules can be totally 
avoided (Kingsmore, 2006). In terms of micro- and nano-technologies enabled optical techniques 
for label-free biodetection, the widely used ones include surface plasmon resonance (SPR), 
SERS, localized SPR, light scattering, photonic crystals, nanoholes, quantum dots, microspheres 
(Ren et al., 2007), opto-fluidic ring resonators (Gohring et al., 2010), microring resonators 
(Washburn et al., 2009), and thin film interferometric devices (Lin et al., 1997). These 
technologies can provide exceptional sensitivity and some of them can even offer detection limit 
down to the single molecule level, hence having great potentials for the early stage detection of 
cancer/disease biomarkers. Specifically, using these technologies, the detection of a variety of 
disease biomarkers such as carcinoembryonic antigen (CEA) for colon cancer, prostate-specific 
antigen (PSA) for prostate cancer, HER2 for breast cancer and amyloid-beta derived diffusible 
ligands (ADDLs) for Alzheimer disease has been demonstrated (Georganopoulou et al., 2005). 
However, the aforementioned techniques still face some of the following issues: the complexity 
of the optical testing setup, expensive micro- or nano-fabrication process, or relative difficulty of 
miniaturization for fabricating integrated microchips. Recently, a class of inexpensive polymer-
based nanostructured Fabry–Perot interferometer (FPI) optical microdevices has been developed 
(Zhang et al., 2010a, 2011). However, the anodic aluminum oxide (AAO) nanostructures inside 
the microdevices were fabricated from Al foil, which is not compatible with a standard 
lithography-based micro- or nano-fabrication process. As a result, it is impossible to fabricate 
arrayed nanostructured FPI optical devices in a cost-effective manner. 
 
Herein, a new set of nanostructured FPI devices fabricated from the lithographically patterned 
AAO nanostructures on ITO glass substrates and its detection of prostate cancer biomarker free 
prostate-specific antigen (f-PSA) are reported for the first time. More specifically, compared to 
all other reported nanopore thin film based biosensors (Lin et al., 1997; Pacholski et al., 2006; 
Zhang et al., 2011), it is the first time to fabricate this type of arrayed sensors on a single chip, 
making the integration of arrayed sensors and microfluidic network much simple and cost-
effective. PSA is a protein produced by cells of the prostate gland and has been used to detect 
prostate cancer at its early stage. Two forms of PSA, free or attached to a protein molecule, 
circulate in the blood. Usually a PSA level below 4.0 ng/mL is regarded as normal (Thompson et 
al., 2004). An elevated PSA level (>4 ng/mL) might be a sign of prostatitis, enlarged prostate or 
prostate cancer. Under benign prostate conditions, there is more f-PSA. Hence the lower the f-
PSA in serum, the higher the possibilities of the prostate cancer. Fig. 1(a) illustrates the 
schematic and operational principle of the nanostructured Fabry–Perot interferometer (FPI) 
microchip. Inside the FPI cavity is a layer of nanopore structures coated with Au thin film. The 
optical transducing signal is the reflected optical interference signal from the nanostructured FPI 
microchip when a white light is incident normally on it. The close-up of the nanostructured FPI 
is shown in Fig. 1(b). When the biomolecules (e.g., antibody) are immobilized on the 
nanostructures and the binding between biomolecules (e.g., between antibody and biomarker) 
occur, the fringes of the reflected signals will shift due to the change of the effective refractive 
index inside the cavity. The nanostructure inside the FPI cavity increases the binding sites of the 
biomolecules thus the sensing surface area up to at least two orders of magnitude larger than that 
of a conventional FPI microdevice with a planar surface inside its cavity. In addition, the Au-
coated nanostructure will enhance the transducing signals tremendously due to the localized 
surface Plasmon resonance effect. A photo of the fabricated 2×2 nanostructured FPI chips is 
shown in Fig. 1(c). 
 
 
 
2. Methods and materials 
 
2.1. Fabrication of nanostructured optical device and microfluidic interface assembly 
 
The fabrication process flow is illustrated in Fig. 2. Briefly, this process starts from an ITO glass 
substrate. A lift-off process is used to form the Al patterns. As a result, Al patterns are formed 
and connected with each other with Al lines as shown in Fig. 2(b). Once the Al patterns have 
been fabricated and cleaned with acetone and DI water, two-step anodization using oxalic acid 
has been carried out to form AAO nanostructures as shown in Fig. 2(c). Then a layer of Au thin 
film (10, 15 and 50 Å) was coated on AAO with a layer of Cr (5 Å) as an adhesion layer. A 
polydimethylsiloxane (PDMS) microfluidic chip was fabricated separately using a soft 
lithography process described in Fig. 2(e) and then was bonded with the AAO-glass chip 
followed by assembling input and output tubing as shown in Fig. 2(f). The input tube was 
connected with a syringe controlled by a syringe pump while the output tube leaded to a 
biochemical waste collecting beaker. It should be noted that the Au-coated AAO patterns were 
totally inside the FPI cavity as shown in Fig. 1(c) in order to ensure that the PDMS microfluidic 
layer was directly bonded to the glass, thus avoiding any liquid leakage during the operation of 
the nanostructured FPI microchip. The SEM images of the fabricated AAO are shown in Fig. 
2(g–h). The detailed fabrication process of the arrayed nanostructured FPI devices can be found 
in supplementary material. 
 
 
 
Three sets of nanostructured FPI microchips have been fabricated and each microchip has four 
identical devices as shown in Fig. 1(c) for the following experiments: (i) Set I: monitoring of the 
self-assembled monolayer (SAM) formation and upper detection range measurement; (ii) Set II: 
determination of the limit-of-detection, and (iii) Set III: control experiments on specificity and 
selectivity of the bioassay. The nanopore size is the same for all microdevices in the three sets, 
but the thickness of Au thin film is different, which gives essentially the similar optical 
performance (i.e., optical contrast), even though the transducing signals (i.e, positions of the 
fringe peaks) from the nanostructured FPI microdevices have some difference (Zhang et al., 
2010a). 
 
2.2. Instrumentation 
 
A broadband light source from a tungsten halogen lamp with spectrum covering 350–1050 nm is 
coupled to a specifically designed optical fiber probe (Ocean Optics, Inc), which illuminates the 
microchip perpendicularly as shown in Fig. 1(a–b) (Zhang et al., 2010b). The reflected signals 
(transducing signals) are collected by the same optical fiber probe, leading to an optical 
spectrometer (Ocean Optics, Inc), which is connected to a laptop computer for data acquisition 
and processing. The biochemical samples are transported to the microdevice through the 
assembled plastic tubing (Upchurch Scientific, Inc.) by a syringe controlled by a syringe pump 
(KD Scientific, Inc.). 
 
2.3. Chemicals and materials 
 
11-Mecaptoundecanoic acid (HSC10COOH, 99%), 8-Mercapto-1-Octanol (HSC8OH, 98%), N-
(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide 
(NHS), and glycine were purchased from Sigma-Aldrich (Milwaukee, WI) and used without 
further purification. Mouse anti-human prostate-specific antigen (PSA) monoclonal antibody 
(detector mAb) (cat.# T40081B, clone # CHYH2), ELISA kits for human free-PSA (Cat.# 
10050) were obtained from Anogen-YES Biotech Laboratories Ltd. (Mississauga, Canada). The 
10 ng/mL free-PSA standard solution was used for preparation of free-PSA solutions with lower 
concentrations using sample dilutant provided in the ELISA kit. The 10 ng/mL free-PSA 
standard solution was prepared in a protein matrix solution according to the WHO standard by 
the vendor. The concentrations of diluted free-PSA include 0, 5, 10, 50, 100, 500, 5000 pg/mL 
for the experiments. Absolute ethanol was obtained from Thermo Fisher Scientific Inc., USA. 
Dionized (DI) water was obtained from a DI water purification system (Millipore, FRANCE). 
Bovine serum albumin (BSA) was obtained from Bio-Rad Laboratories, USA. It was diluted 
with PBS (pH=7.2) solution at several different concentrations of 50, 100, 500, 5000 pg/mL for 
the control experiments. Rabbit Immunoglobulin G (Rabbit-IgG) was purchased from Sigma-
Aldrich and was diluted using PBS (pH=7.2) solution to several different concentrations of 50, 
100, 500, 5000 pg/mL for the control experiments. 
 
2.4. Biodetection procedures 
 
2.4.1. Immobilization of detector mAb on the gold surface 
 
 
 
2.4.2. f-PSA detection 
 
Once the antibodies (mAbs) have been immobilized on the gold-coated nanostructured surface in 
the microchip, the detection of f-PSA was ready as shown in Fig. 3. The f-PSA is the unbounded 
form of the antigen and normally at the level of 10% of total PSA. A higher amount of f-PSA in 
a test means a lower chance of cancer. During the experiments, PBS was used as a running 
buffer to help minimize or avoid the nonspecific adsorption of the f-PSA in the tubes and the 
microfluidic channels. 
 
2.4.3. Control experiment 
 
Two types of control experiments have been designed and carried out to evaluate the 
specificity/selectivity of the immunoassay using the nanostructured FPI microdevices. 
Specifically, the binding between the detector mAb and BSA at concentrations of 50, 100, 500, 
5000 pg/mL has been evaluated, respectively. In addition, the binding between the detector mAb 
and rabbit IgG at several different concentrations has also been evaluated. 
 
2.5. Experimental data analysis 
 
The average shift of the fringes for the measured transducing signals is obtained by (i) first 
obtaining the shift of each fringe peak relative to that of the blank Au-coated nanostructure 
surface or that after the antibodies (mAbs) have been immobilized on the nanostructure surface, 
then (ii) averaging the shift of all the peaks. The reference for each average shift is specified in 
the context in the following sections. 
 
The effective optical thickness (EOT) of the nanostructure layer and the biomolecules 
immobilized on it is obtained by performing Fourier transform on the measured optical 
transducing signals, which were described in detail in the citation (Zhang et al., 2010a). A 
MATLAB program based on the fast Fourier transform algorithm has been developed for this 
calculation. 
 
3. Results and discussion 
 
3.1. Surface functionalization of the Au-coated nanostructures 
 
The surface functionalization of the Au-coated nanostructures was performed step by step 
following the protocol illustrated in Fig. 3. It is a well-established method to form a mixed SAM 
of alkanethiols by the adhesion reaction of the thiol group on gold surface (Cass and Ligler, 
1998). The monolayer is well packed and the tethered carboxylic acid is easy to be 
functionalized for biological molecule immobilization (Wei et al., 2004). Upon the presence of 
EDC/NHS, the carboxylic groups form active O-acylisourea intermediates, and readily react with 
primary amine groups which exist at the N-terminus of each polypeptide chain and in the side 
chain of lysine (Lys, K) residues. Because of their positive charge at physiologic conditions, 
primary amines are usually outward-facing (i.e., on the outer surface) of proteins; hence, they are 
usually accessible for conjugation without denaturing protein structure. In such a way, the 
detector mAbs for f-PSA are covalently attached to the top of the mixed SAMs. The remaining 
active O-acylisourea intermediate groups are deactivated by the amino acid glycine to avoid non-
specific biological attachment caused by the intermediates. At this stage, the mAbs are 
conjugated to the nanostructured surface and ready for f-PSA detection. 
 
Since each aforementioned surface chemical modification step changes the local refractive index 
and the effective optical thickness of the nanostructured surface, hence each step can be 
monitored optically in real time. The real-time monitoring experiments have been carried out on 
four individual nanostructured FPI microchips in the Set I, giving consistent results. As an 
example, Fig. 4(a) gives a representative step-by-step measurement during the surface 
functionalization. As we can see, the interference fringes (transducing signals) shift clearly after 
each step of addition of organic molecules and biomolecules. It should be noted that all these 
measurements were performed at room temperature. The measured interference fringes for the 
antibody attachment were obtained after totally 2-hour incubation and three cycles of rigorous 
PBS solution rinsing. Compared to the fringes obtained on the nanostructured FPI microchip 
with a blank gold-coated nanostructured surface in the range of 550–850 nm, typical average 
shift was 5.13±0.02 nm after the HSC10COOH/HSC8OH was added and reacted with the gold-
coated surface, 9.48±0.02 nm after EDC/NHS was added and reacted with the surface, 
13.68±0.02 nm after the antibodies (mAbs) were added and attached to the surface. 
 
 
 
The more detailed real-time monitoring of the process of the attachment of antibodies (mAbs) is 
given in Fig. 4(b). When the mAbs were flowed into the chip, the optical signals were monitored 
at different time interval. As we know that it would take some time for antibodies to be 
immobilized and attached to the SAM layer. The measurements showed clearly the shift of the 
fringes after 1-hour incubation at room temperature relative to that of pre-antibody being applied. 
The shift further increased after 2-hour incubation, indicating that possibly more antibodies had 
been immobilized or attached. Thereafter, three-time rigorous rinsing by flowing PBS solution 
was carried out to remove the unbounded or loosely bounded antibodies. As expected, the shift 
of the fringes decreased relative to that of pre-antibody attached condition, namely the fringes 
had a red-shift. Experiments found that after 3 cycles of rinsing using PBS solution, no further 
shift of the fringes was observed, suggesting that all the unbounded antibodies had been got rid 
of from the microchip. Compared to the fringes of pre-attachment of the antibodies, the 
measured final average fringe shift was 4.21±0.02 nm after antibodies were attached and 
immobilized. Thereafter, a glycine PBS solution is applied to avoid non-specific binding 
between SAM and f-PSA, negligible shift of the fringes has been observed as shown in Fig. 4(c), 
indicating that the active sites at SAM have been totally or almost totally occupied by mAbs, and 
thus no or very few amino acid glycine is attached to them. 
 
The real-time monitoring of the transducing signals is an important step to verify that each 
chemical modification of the sensing surface has actually occurred. This measurement is 
particularly useful and effective since we do not need utilize any fluorescent dyes to tag the 
organic molecules or biomolecules to visually observe and thus confirm the occurrence of each 
surface modification. In addition, it is also a simple approach to ensure that the unbounded and 
loosely bounded molecules have been totally rinsed away. This is a critical step to warrant the 
consistent measurements from each microchip, especially for future reliable and reproducible 
arrayed microchips for multiplexed biodetection. 
 
3.2. Detection of cancer biomarker free-PSA 
 
After the antibodies (mAbs) are immobilized on the Au-coated nanostructured surface inside the 
microchip, the quantitative measurement of f-PSA can be carried out. 
 
3.2.1. Upper detection range 
 
The effect of the amount of the antibodies immobilized on the microchips on the upper detection 
range of the f-PSA has been evaluated. In this set of experiments, the antibody (mAb) 
concentration was 10 μg/mL and the incubation time was 2 h. The concentrations of f-PSA 
flowed into the microchip were 100, 500 and 5000 pg/mL in a PBS solution. The order of the 
experiments was designed as the following. The f-PSA was flowed into microchip from lower 
concentration to higher concentration sequentially. For instance, the f-PSA at concentration of 
100 pg/mL was flowed into the chip first, after 45 min incubation, PBS solution was flowed to 
rinse the microchip three times and measurements were carried out accordingly. Then the f-PSA 
at higher concentrations (i.e., 500 and 5000 pg/mL) were flowed into the chip. After incubation, 
a rinsing and measurement routine was carried out again. It was found that the binding sites had 
been almost totally occupied after f-PSA at concentration of 500 pg/mL was flowed into the chip 
since the interference fringes remained essentially unchanged even more f-PSA was added. As 
an example, the measurement in Fig. 4(d) shows that when the concentration of f-PSA reached 
5000 pg/mL, there was little observable shift of the fringes compared to that of f-PSA at a 
concentration of 500 pg/mL, indicating the upper detection range of f-PSA was about 500 
pg/mL. If we want to expand the upper detection range, basically we have to immobilize more 
antibodies on the microchip so that more binding sites are available for f-PSA. However, it 
should be also noted that the amount of the antibodies cannot be too excessive; otherwise the 
antibodies immobilized on the sensing surface are too closely packed and crowded to allow f-
PSA to approach the binding sites efficiently and consequently to be attached to them. For 
instance, in one of our experiments, antibodies (mAbs) at a concentration of 100 μg/mL were 
immobilized on the sensing surface with 24-hour incubation, the f-PSA at several concentrations 
was flowed into the chip for the testing. After rinsing by the PBS solution, it turned out that 
essentially no f-PSA had been attached to the antibodies, resulting in negligible shift in the 
fringes. 
 
3.2.2. Limit of detection (LOD) 
 
The experiments were carried out on four individual microchips in Set II. All the measurements 
gave consistent results. In this case, the antibodies at a concentration of 10 μg/mL were flowed 
into the chip with incubation time of 4 h. The concentrations of f-PSA flowed into the microchip 
were 0, 5, 10, 50, 100 and 500 pg/mL in a PBS solution. The f-PSA was flowed into microchip 
from lower concentration to higher concentration sequentially. Specifically, the f-PSA at 
concentration of 0 pg/mL was flowed into the chip first, after sufficient time (45 min) for 
incubation, the PBS solution was flowed to rinse the microchip three times and measurements 
were carried out. Thereafter, the f-PSA at concentration of 5 pg/mL was flowed into the 
microchip for the testing. After 45-minute incubation, a rinsing and measurement routine was 
carried out. Similarly, the experiments were performed for f-PSA at concentrations of 10, 50, 
100, and 500 pg/mL in sequence, respectively. All these results were obtained by multiple 
measurements on four individual microchips, and the average fringe shift for each concentration 
was obtained accordingly. 
 
Fig. 5(a–b) shows a representative measurement of the transducing signals with the f-PSA 
flowed into microchip at concentrations of 0, 5, 10, and 100 pg/mL. As expected, the 
interference fringes showed no or negligible shift with the f-PSA at 0 pg/mL since no f-PSA was 
actually available to be bounded to the antibodies. The average shift of the fringes was about 
2.19±0.02 nm with the f-PSA at a concentration of 5 pg/mL in the range of 550–850 nm, relative 
to the fringes for the device with immobilized antibodies. By increasing the concentration of the 
f-PSA to 10, 50, 100, and 500 pg/mL in sequence, the average fringe shift increased as expected 
since increasing amount of f-PSA were bounded to the antibodies. Experiments have also found 
that the fringe shift was not clearly distinguishable when the concentration of the f-PSA was 
below 5 pg/mL using these microchips for the experiments. This might be due to the resolution 
limit (±0.02 nm) of the optical spectrometer used in the experiments or the detection limit of 
these microchips, indicating that the lowest detectable concentration of f-PSA by current 
microchips is about 5 pg/mL. 
 
 
 
Fourier transform has been applied on the measured transducing signals, and the effect optical 
thickness (EOT) of the nanostructured layer and the biomolecules immobilized on it has been 
obtained. Using the EOT after the immobilization of the antibodies as a reference, which is 
7487±2 nm, the change of the EOT (ΔEOT) after applying f-PSA at different concentrations has 
been obtained. In Fig. 5(c), the change of the effective optical thickness (ΔEOT) under different 
concentrations of the f-PSA is summarized. As expected, the lower concentration of the f-PSA, 
the less the f-PSA was bounded to the antibodies, hence the smaller the ΔEOT. The EOT for 
each case was obtained by averaging several measurements. As can be seen, the ΔEOT has a 
linear dynamic range with the concentration of f-PSA from 10 to 500 pg/mL. However, at 5 
pg/mL of f-PSA, the lowest detectable concentration, its ΔEOT has a relatively big change and 
deviated from the linear relationship, which might be related to the experiment procedure 
performed by increasing the concentration of the f-PSA. Hence, at current stage and for safety, 
the limit-of-detection (LOD) of the sensor is about10 pg/mL or lower, which is ∼280 fM, for the 
detection of f-PSA. 
 
Finally, the control experiments have been carried out on the microchips in the Set III to 
demonstrate the specificity and selectivity of the bioassay. In this case, the incubation time of 
antibodies at a concentration of 10μg/mL was 4 h. The BSA solutions with different 
concentrations of 50, 100, 500 and 5000 pg/mL have been flowed into the microdevice 
sequentially. For each concentration of BSA, the incubation time was 60 min, followed by 
rigorous PBS solution rinsing three times. Representative measurements are given in Fig. 5(d). 
No or negligible shift in fringes has been observed when the BSA with four different 
concentrations was applied to the microchips, confirming the specific recognition between the 
antibodies (mAbs) and the f-PSA. Similarly, we performed experiments to check if the 
antibodies were bounded to rabbit IgG at concentrations of 50, 100, 500 and 5000 pg/mL, 
respectively. No or negligible shift in the fringes has been observed, indicating again that the 
antibodies were only specific to the f-PSA. Overall, these two types of control experiments (BSA 
and rabbit IgG) suggest the excellent selectivity of the immunoassay. 
 
It should be noted that even though the three sets of devices have somewhat different transducing 
signals (i.e. the positions of the fringe peaks were different), for each set of the devices, a 
nanostructured FPI microchip with a blank gold-coated nanostructured surface from the same set 
was used as the reference, hence consistent measurement results for the bioassay have been 
obtained for the aforementioned three types of tests. In addition, it should be noted that the 
incubation time for the antibodies is unnecessary to be 2 or 4 h as confirmed by the experimental 
results in Fig. 4(b). In contrast, about 1.5-hour incubation time for the antibodies is sufficient. 
Actually with 2-hour or 4-hour incubation, significant amount of the antibodies is still 
unbounded due to no more available binding sites and will be removed by PBS solution rinsing. 
 
As demonstrated, the nanostructured FPI microchips can offer sufficient sensitivity for the 
detection of clinically relevant cancer biomarkers, which are typically in the range of picomolar 
concentration level or lower. Furthermore, even though this paper only reports the detection of 
one cancer biomarker, since arrayed microchips can be batch-fabricated in an inexpensive and 
efficient manner, a disposable platform based on arrayed nanostructured FPI microchips can be 
developed for the multiplexed biomolecular detection and analysis in the future. 
 
4. Conclusions 
 
In summary, the detection of f-PSA has been demonstrated using nanostructured FPI microchips 
successfully. It has been demonstrated that the chemical and biochemical functionalization of the 
nanostructured sensing surface can be monitored in real-time. The upper dynamic detection 
range can be changed by varying the amount of capture antibodies immobilized on the sensing 
surface. Currently the limit-of-detection (LOD) of the nanostructured FPI microchip for f-PSA is 
about 10 pg/mL or lower, which could be further lowered down by optimizing the optical 
properties (e.g., finesse) of the microchips. Experiments have also demonstrated the high 
specificity and selectivity of the immunoassay used in the biosensing, indicating the great 
promise for the detection of cancer biomarkers at trace levels in biofluids. Finally, due to the 
feasibility of fabricating hundreds of nanostructured FPI microdevices on a single chip, this 
technical platform offers great potential for highly multiplexed, label-free biodetection for the 
diagnosis of various cancers or diseases in a clinic setting and for anticancer drug screen and 
discovery applications. 
 
Acknowledgments 
 
The research is funded in part by NSF CAREER Award ECCS0845370 and NSF-Pfund 2009. 
 
References 
 
Ackermann, B., Hale, J., Duffin, K., 2006. Current Drug Metabolism 7, 525–539.  
 
Cass, T., Ligler, F., 1998. Immoblized Biomolecules in Analysis: A Practical Approach. Oxford 
University Press, UK. 
 
Chan, L., Gosangari, S., Watkin, K., Cunningham, B.T., 2008. Sensors and Actuators B 132, 
418–425. 
 
Choe, L., Werner, B., Lee, K., 2006. NeuroRx : The Journal of the American Society for 
Experimental NeuroTherapeutics 3, 327–335. 
 
Choi, Y., Kwak, J., Park, J., 2010. Sensors 10, 428–455. 
 
Farwell, L., Joshi, V., 2009. Methods in Molecular Biology (Clifton, NJ) 520, 205–220. 
 
Ferrari, M., 2005. Nature Reviews Cancer 5, 161–171. 
 
Food, S., Pirrung, M., Stryer, L., Lu, A., Solas, D., 1991. Science (New York, NY) 251, 767–
773. 
 
Gao, X., Cui, Y., Levenson, R., Chung, L., Nie, S., 2004. Nature Biotechnology 22, 969–976. 
 
Gaster, R., Hall, D., Nielsen, C., Osterfeld, S., Yu, H., Mach, K., Wilson, R., Murmann, B., Liao, 
J., Gambhir, S., Wang, S., 2009. Nature Medicine 15, 1327–1332. 
 
Georganopoulou, D., Chang, L., Nam, J., Thaxton, C., Mufson, E., Klein, W., Mirkin, C., 2005. 
Proceedings of the National Academy of Sciences of the United States of America 102 (7), 
2273–2276. 
 
Gohring, J., Dale, P., Fan, X., 2010. Sensors and Actuators B 146, 226–230. Haynes, C., 
McFarland, A., Van Duyne, R., 2005. Analytical Chemistry, 338–346.  
 
Healy, D., Hayes, C., Leonard, P., McKenna, L., O’Kennedy, R., 2007. Trends in Biotechnology 
25, 125–131. 
 
Henne, W., Doorneweerd, D., Lee, J., Low, P., Savran, C., 2006. Analytical Chemistry 78 (14), 
4880–4884. 
 
Imafuku, Y., Omenn, G., Hanash, S., 2004. Disease Markers 20, 149–153. Kingsmore, S., 2006. 
Nature Reviews Drug Discovery, 1–11. 
 
Lee, H., Wark, A., Corn, R.M., 2008. Analyst 133 (8), 975–983. 
 
Lin, V., Motesharei, K., Dancil, K., Sailor, M., Ghadiri, M., 1997. Science (New York, NY) 278, 
840–843. 
 
Liu, X., Dai, Q., Austin, L., Coutts, J., Knowles, G., Zou, J., Chen, H., Huo, Q., 2008. Journal of 
the American Chemical Society 130, 2780–2782. 
 
Mukundan, H., Xie, H., Anderson, A., Grace, W., Shively, J., Swanson, B., 2009. Bioconjugate 
Chemistry 20 (2), 222–230. 
 
Nie, S., Emory, S., 1997. Science (New York, NY) 275, 1102–1106. 
 
Pacholski, C., Yu, C., Miskelly, G.M., Godin, D., Sailor, M.J., 2006. Journal of the American 
Chemical Society 128, 4250–4252. 
 
Petricoin, E., Rajapaske, V., Herman, E., Arekani, A., Ross, S., Johann, D., Knapton, A., Zhang, 
J., Hitt, B., Conrads, T., Veenstra, T., Liotta, L., Sistare, F., 2004. Toxicologic Pathology 32 
(Suppl 1), 122–130. 
 
Ren, H., Vollmer, F., Arnold, S., Libchaber, A., 2007. Optics Express 15, 17410–17423. 
 
Smith, E., Corn, R., 2003. Applied Spectroscopy 57 (11), 320A–332A. 
 
Star, A., Tu, E., Niemann, J., Gabriel, J., Joiner, C., Valcke, C., 2006. Proceedings of the 
National Academy of Sciences of the United States of America 103 (4), 921–926. 
 
Stoevesandt, O., Taussig, M., He, M., 2009. Expert Review of Proteomics 6 (2), 145–157. 
 
Thompson, I., Pauler, D., Goodman, P., et al., 2004. New England Journal of Medicine 350 (22), 
2239–2246. 
 
Tian, R., Regonda, S., Gao, J., Lin, Y., Hu, W., 2011. Lab on a Chip 11, 1952–1961. Washburn, 
A., Gunn, L., Bailey, R.C., 2009. Analytical Chemistry 81 (22), 9499–9506. 
 
Wei, J., Liu, Y., Niki, K., Margoliash, E., Waldeck, D., 2004. Journal of Physical Chemistry B 
108, 16912–16917. 
 
Wilson, B., Nie, W., 2006. Analytical Chemistry 78, 6476–6483. 
 
Wu, G., Datar, R., Hansen, K., Thundat, T., Cote, R., Majumdar, A., 2000. Nature 
Biotechnology 19, 856–860. 
 
Yanik, A., Cetin, A., Huang, M., Artar, A., Mousavi, S., Khanikaev, A., Connor, J., Shvets, G., 
Altug, H., 2005. Proceedings of the National Academy of Sciences of the United States of 
America 108 (29), 11784–11789. 
 
Zangar, R., Daly, D., White, A., 2006. Expert Review of Proteomics 3, 37–44.  
 
Zhang, T., Gong, Z., Giorno, R., Que, L., 2010a. Optics Express 18 (19), 20282–20288. Zhang, 
T., Pathak, P., Karandikar, S., Giorno, R., Que, L., 2011. Biosensors and Bioelectronics 30, 128–
132. 
 
Zhang, T., Talla, S., Gong, Z., Karandikar, S., Giorno, R., Que, L., 2010b. Optics Express 18 
(17), 18394–18400. 
 
Zheng, G., Patolsky, F., Cui, Y., Wang, W., Lieber, C.M., 2005. Nature Biotechnology 23 (10), 
1294–1301. 
 
Zhou, L., Ou, L., Chu, X., Shen, G., Yu, R., 2007. Analytical Chemistry 79 (19), 7492–7500. 
